Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-ranging safety and pharmacokinetics study of candesartan cilexetil in hypertensive pediatric subjects 1 to less than 6 years of age: a 4-week, multicenter, randomized, double-blind study with a 1-year, open-label, follow-up period

Next Previous
X
Search
Trial Profile

A dose-ranging safety and pharmacokinetics study of candesartan cilexetil in hypertensive pediatric subjects 1 to less than 6 years of age: a 4-week, multicenter, randomized, double-blind study with a 1-year, open-label, follow-up period

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CINCH
  • Sponsors AstraZeneca

    • Most Recent Events

    • 09 Nov 2012 Planned number of patients changed from 82 to 125 as reported by European Clinical Trials Database.
    • 12 Feb 2010 Results published in Journal of Hypertension.
    • 12 Feb 2010 Primary endpoint 'Systolic blood pressure' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top